Stocks News

LAST PRICE
34.0400
TODAY'S CHANGE (%)
Trending Down-0.2400 (-0.7001%)

Bid / Lots
33.9100/ 1
Ask / Lots
34.0700/ 4
Open / Previous Close
34.7400 / 34.2800
Day Range
Low 33.9100
High 36.3800
52 Week Range
Low 25.6000
High 77.6000
Volume
256,283
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- DJ Disc Medicine Price Target Maintained With a $85.00/Share by Cantor Fitzgerald, from 3 hours ago by Dow Jones
  3 hours ago by Dow Jones
  Companies Mentioned: IRON
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IRON/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 28, 2024 09:52 ET (13:52 GMT)
May 15, 2024
- DJ Disc Medicine Price Target Maintained With a $85.00/Share by Cantor Fitzgerald, from 8:12AM ET on Wednesday May 15, 2024 by Dow Jones
  8:12AM ET on Wednesday May 15, 2024 by Dow Jones
  Companies Mentioned: IRON
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IRON/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 15, 2024 08:12 ET (12:12 GMT)
May 14, 2024
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress, from 10:30AM ET on Tuesday May 14, 2024 by GlobeNewswire
  10:30AM ET on Tuesday May 14, 2024 by GlobeNewswire
  Companies Mentioned: IRON
- Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress, from 10:30AM ET on Tuesday May 14, 2024 by Dow Jones
  10:30AM ET on Tuesday May 14, 2024 by Dow Jones
  Companies Mentioned: IRON
  
  Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
  -- Additional analyses of data from AURORA, as well as the full adult data set from BEACON -- Updated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a larger data set and longer follow-up, to be shared in a poster -- Preliminary data on safety and pharmacodynamic activity from initial single-ascending dose (SAD) cohorts of phase 1 study of DISC-3405 in healthy volunteers
May 13, 2024
- Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference, from 8:00AM ET on Monday May 13, 2024 by GlobeNewswire
  8:00AM ET on Monday May 13, 2024 by GlobeNewswire
  Companies Mentioned: IRON

Today
- Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting, from 5 hours ago by Business Wire
  5 hours ago by Business Wire
  Companies Mentioned: SRRK
May 26, 2024
- INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 11:08AM ET on Sunday May 26, 2024 by Accesswire
  11:08AM ET on Sunday May 26, 2024 by Accesswire
  Companies Mentioned: SPRY
May 25, 2024
- IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 11:07AM ET on Saturday May 25, 2024 by Accesswire
  11:07AM ET on Saturday May 25, 2024 by Accesswire
  Companies Mentioned: SPRY
May 24, 2024
- SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 1:30PM ET on Friday May 24, 2024 by Accesswire
  1:30PM ET on Friday May 24, 2024 by Accesswire
  Companies Mentioned: SPRY
May 23, 2024
- IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 7:18PM ET on Thursday May 23, 2024 by Accesswire
  7:18PM ET on Thursday May 23, 2024 by Accesswire
  Companies Mentioned: SPRY
May 22, 2024
- INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 6:17PM ET on Wednesday May 22, 2024 by Accesswire
  6:17PM ET on Wednesday May 22, 2024 by Accesswire
  Companies Mentioned: SPRY
- Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity, from 10:54AM ET on Wednesday May 22, 2024 by MT Newswires
  10:54AM ET on Wednesday May 22, 2024 by MT Newswires
  Companies Mentioned: SRRK
- Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity, from 7:00AM ET on Wednesday May 22, 2024 by Business Wire
  7:00AM ET on Wednesday May 22, 2024 by Business Wire
  Companies Mentioned: SRRK
May 21, 2024
- DEADLINE ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 3:31PM ET on Tuesday May 21, 2024 by Accesswire
  3:31PM ET on Tuesday May 21, 2024 by Accesswire
  Companies Mentioned: SPRY
May 20, 2024
- ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 9:05PM ET on Monday May 20, 2024 by Accesswire
  9:05PM ET on Monday May 20, 2024 by Accesswire
  Companies Mentioned: SPRY

Disc Medicine Inc
NASDAQ:IRONUnited States

Search Criteria

Today

DJ Disc Medicine Price Target Maintained With a $85.00/Share by Cantor Fitzgerald, from 3 hours ago by Dow Jones

May 15, 2024

DJ Disc Medicine Price Target Maintained With a $85.00/Share by Cantor Fitzgerald, from 8:12AM ET on Wednesday May 15, 2024 by Dow Jones

May 14, 2024

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress, from 10:30AM ET on Tuesday May 14, 2024 by GlobeNewswire

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress, from 10:30AM ET on Tuesday May 14, 2024 by Dow Jones

May 13, 2024

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference, from 8:00AM ET on Monday May 13, 2024 by GlobeNewswire

Peers Headlines

Today

Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting, from 5 hours ago by Business Wire

May 26, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 11:08AM ET on Sunday May 26, 2024 by Accesswire

May 25, 2024

IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 11:07AM ET on Saturday May 25, 2024 by Accesswire

May 24, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 1:30PM ET on Friday May 24, 2024 by Accesswire

May 23, 2024

IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 7:18PM ET on Thursday May 23, 2024 by Accesswire

May 22, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 6:17PM ET on Wednesday May 22, 2024 by Accesswire

Scholar Rock Starts Phase 2 Trial of Apitegromab in Obesity, from 10:54AM ET on Wednesday May 22, 2024 by MT Newswires

Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity, from 7:00AM ET on Wednesday May 22, 2024 by Business Wire

May 21, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 3:31PM ET on Tuesday May 21, 2024 by Accesswire

May 20, 2024

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, from 9:05PM ET on Monday May 20, 2024 by Accesswire